E2 (Endovascular Engineering) Raises $80 Million Series C to Advance Next-Generation Thrombectomy Platform as Pulmonary Embolism Treatment Evolves
Gilde Healthcare and Norwest co-led round to commercialize the Hēlo® Thrombectomy Platform MENLO PARK, Calif., April 7, 2026 /PRNewswire/ — Endovascular Engineering, Inc. (“E2”), a commercial-stage medical technology company focused on advancing the treatment of venous thromboembolism (VTE),…